NeuroPace, the developer of the RNS implantable brain stimulator for the treatment of drug-refractory focal epilepsy, hopes to raise $75m in an initial public offering.
On 24 March, the Silicon Valley company filed an S-1 registration statement with the US Securities and Exchange Commission,...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?